|Bid||0.00 x 1400|
|Ask||0.00 x 1200|
|Day's range||9.57 - 10.28|
|52-week range||2.43 - 51.03|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||11 May 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||8.58|
Investors need to pay close attention to Tilray (TLRY) stock based on the movements in the options market lately.
Shares of Canopy growth (CGC) are trading 30% lower since its latest quarterly results last week. However one analyst sees share as undervalued for the Canadian cannabis company which has shifted from medical to more recreational sales when that market was legalized in Canada almost two years ago. “Although we expect the medical market to shrink because of recreational legalization, we forecast more than 10% average annual growth for the entire Canadian market through 2030, driven by the conversion of black-market consumers into the legal market and new cannabis consumers,” analyst Kristoffer Inton wrote in a note to investors.
A pair of marijuana stocks, Tilray (NASDAQ: TLRY) and OrganiGram Holdings (NASDAQ: OGI), both dropped notably in price on Friday (by 5.2% and 7%, respectively). The culprit seems to be another weed title, Canopy Growth (NYSE: CGC), which earlier in the day published an awful quarterly earnings release. Canopy Growth is a leading company in the sector.
Inside the best performing stocks in the top cannabis ETF of May.
Tilray, Inc. ("Tilray" or the "Company") (NASDAQ: TLRY), a global pioneer in cannabis research, cultivation, production and distribution, today announced its wholly-owned subsidiary Tilray Portugal, Unipessoal Lda. ("Tilray Portugal") has received a Good Manufacturing Practice (GMP) certification in accordance with European Union standards, for its manufacturing facility in Cantanhede, Portugal. The GMP certification was issued by Infarmed, the Portuguese National Authority of Medicines and Health Products which provides end-to-end GMP certification for Tilray’s current operations in Portugal.
Tilray, Inc. ("Tilray" or "the Company") (NASDAQ: TLRY), a global pioneer in cannabis research, cultivation, production and distribution, today announced its wholly-owned subsidiary High Park Gardens ("Natura Naturals Inc.") will close its doors over the course of the next six weeks. As a result of the closure, the Company expects to realize annualized net savings of approximately $7.5 million (current production costs net of future 3rd party purchases and ongoing depreciation) and avoid significant ongoing capital expenditures.
Canadian cannabis company Tilray's (NASDAQ: TLRY) CEO believes that at least 12 marijuana companies will go under this year. In March, Tilray announced that it would be raising $90.4 million through an offering, largely because the company still could. CEO Brendan Kennedy told BNN Bloomberg that he "wasn't sure anyone was going to be able to raise any money in this industry again" and that "when we had the opportunity to strengthen the balance sheet, we did."
Ladies and gentlemen, thank you for standing by, and welcome to Tilray's First Quarter 2020 Earnings Conference Call. Good afternoon, and thank you for joining us on Tilray's first quarter 2020 earnings conference call and webcast. On with me today are Brendan Kennedy, Chief Executive Officer; and Michael Kruteck, Chief Financial Officer.
Tilray's (NASDAQ:TLRY) 55% year-to-date loss is, without question, really bad. But it could have been much worse. Actually, it was much worse. At one point in March, Tilray had plunged nearly 90%.
Tilray Inc (TLRY) delivered earnings and revenue surprises of -11.36% and 4.85%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Tilray, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY), a global pioneer in cannabis research, cultivation, production and distribution, reports financial results for the first quarter ended March 31, 2020. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.
What happened Tilray (NASDAQ: TIL) shareholders outperformed a strong market last month. The stock rose 17% compared to a 13% increase in the S&P 500, according to data provided by S&P Global Market Intelligence.
Barbuto & Johansson, P.A. (“BARJO”) reminds investors that today is the last day to contact the Firm to learn more about the class action filed against Tilray, Inc. (TLRY), and appointment of lead plaintiff. The class action’s first-filed case, Chad Ganovsky v. Tilray, Inc., et al., Case No.: 20-cv-01240, was filed in the US District Court for the Eastern District of New York on behalf of shareholders who purchased Tilray securities between January 15, 2019 and March 2, 2020, inclusive (the “Class Period”).
Shareholder rights law firm Robbins LLP reminds investors that a purchaser of Tilray, Inc. (NASDAQ: TLRY) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between January 15, 2019 and March 2, 2020. Tilray engages in research, cultivation processing, and distribution of medical cannabis.
The Law Offices of Frank R. Cruz reminds investors of the upcoming May 5, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Tilray, Inc. ("Tilray" or "the Company") (NASDAQ: TLRY) securities between January 15, 2019 and March 2, 2020, inclusive (the "Class Period").
Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action filed on behalf of investors that purchased or acquired the securities of Tilray, Inc. ("Tilray" or the "Company") (NASDAQ: TLRY) between January 15, 2019, and March 2, 2020 (the "Class Period"). The lawsuit filed in the United States District Court for the Eastern District of New York alleges violations of the Securities Exchange Act of 1934.
Tilray Inc. ("Tilray" or the "Company") (Nasdaq: TLRY), a global pioneer in cannabis production, research, cultivation and distribution, announced today it will report results for the first quarter ended March 31, 2020 on Monday, May 11, 2020 after market close.
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have only until May 5, 2020 to file lead plaintiff applications in a securities class action lawsuit against Tilray, Inc. (TLRY), if they purchased the Company’s securities between January 15, 2019 and March 2, 2020, inclusive (the “Class Period”). This action is pending in the United States District Court for the Eastern District of New York. If you purchased securities of Tilray and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (email@example.com), or visit https://www.ksfcounsel.com/cases/nasdaqgs-tlry/ to learn more.
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to firstname.lastname@example.org.